Arterial pathology in canine mucopolysaccharidosis-I and response to therapy

Laboratory Investigation

Volumn 91, Issue 5, 2011, Pages 665-674

  Lyons, Jeremiah A ^a   Dickson, Patricia I ^b   Wall, Jonathan S ^c   Passage, Merry B ^b   Ellinwood, N Matthew ^d   Kakkis, Emil D ^b,e   McEntee, Michael F ^a  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF TENNESSEE GRADUATE SCHOOL OF MEDICINE   (United States)

^d IOWA STATE UNIVERSITY   (United States)

^e BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

atherosclerosis; enzyme replacement therapy; lysosomal storage disease; mucopolysaccharidosis; pathogenesis; vasculopathy

Indexed keywords

CLAUDIN 5; FIBRONECTIN; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LARONIDASE; LEVO IDURONIDASE; TRANSFORMING GROWTH FACTOR BETA1;

ABDOMINAL AORTA; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DISEASE; ARTICLE; ATHEROSCLEROSIS; BASEMENT MEMBRANE; BLOOD VESSEL WALL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOG; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBROBLAST; GENE MUTATION; HETEROZYGOSITY; HOMOZYGOSITY; HURLER SYNDROME; IMMUNOHISTOCHEMISTRY; INTIMA; MACROPHAGE; MALE; NONHUMAN; PRIORITY JOURNAL; SCLEROSIS; SHEAR STRESS; SMOOTH MUSCLE FIBER;

EID: 79955546366     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2011.7     Document Type: Article

References (42)

1. Dorfman A, Matalon R. The mucopolysaccharidoses (a review). Proc Natl Acad Sci USA 1976;73:630-637.
2. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Valle D, Sly WS (eds). The Metabolic and Molecular Bases of Inherited Diseases. McGraw-Hill Professional: New York, NY, 2001, pp 3421-3452.
3. Kakkis ED, Muenzer J, Tiller GE, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001;344:182-188. (Pubitemid 32064139)
4. Muenzer J, Wraith JE, Clarke LA. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 2009;123:19-29.
5. Spellacy E, Shull RM, Constantopoulos G, et al. A canine model of human a-L-iduronidase deficiency. Proc Natl Acad Sci USA 1983;80:6091-6095. (Pubitemid 14228249)
6. Shull RM, Helman RG, Spellacy E, et al. Morphologic and biochemical studies of canine mucopolysaccharidosis I. Am J Pathol 1984;114: 487-495. (Pubitemid 14151585)
7. Shull RM, Munger RJ, Spellacy E, et al. Canine a-L-iduronidase deficiency. A model of mucopolysaccharidosis I. Am J Pathol 1982;109:244-248. (Pubitemid 13234158)
8. Menon KP, Tieu PT, Neufeld EF. Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I. Genomics 1992;14:763-768.
9. Ohmi K, Greenberg DS, Rajavel KS, et al. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 2003;100:1902-1907. (Pubitemid 36254546)
10. Hinek A, Braun KR, Liu K, et al. Retrovirally mediated overexpression of versican v3 reverses impaired elastogenesis and heightened proliferation exhibited by fibroblasts from Costello syndrome and Hurler disease patients. Am J Pathol 2004;164:119-131. (Pubitemid 38364597)
11. Metcalf JA, Linders B, Wu S, et al. Upregulation of elastase activity in aorta in mucopolysaccharidosis I and VII dogs may be due to increased cytokine expression. Mol Genet Metab 2010;99:396-407.
12. Simonaro CM, Ge Y, Eliyahu E, et al. Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci USA 2010;107:222-227.
13. Ma X, Tittiger M, Knutsen RH, et al. Upregulation of elastase proteins results in aortic dilatation in mucopolysaccharidosis I mice. Mol Genet Metab 2008;94:298-304.
14. Ballabio A, Gieselmann V. Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 2009;1793:684-696.
15. Brosius III FC, Roberts WC. Coronary artery disease in the Hurler syndrome. Qualitative and quantitative analysis of the extent of coronary narrowing at necropsy in six children. Am J Cardiol 1981;47:649-653. (Pubitemid 11137663)
16. Taylor DB, Blaser SI, Burrows PE, et al. Arteriopathy and coarctation of the abdominal aorta in children with mucopolysaccharidosis: imaging findings. Am J Roentgenol 1991;157:819-823.
17. Krovetz LJ, Lorincz AE, Schiebler GL. Cardiovascular manifestations of the Hurler syndrome: hemodynamic and angiocardiographic observations in 15 patients. Circulation 1965;31:132-141.
18. Braunlin EA, Berry JM, Whitley CB. Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 2006;98:416-418. (Pubitemid 44062452)
19. Braunlin E, Mackey-Bojack S, Panoskaltsis-Mortari A, et al. Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in Hurler syndrome. Pediatr Res 2006;59:27-32.
20. Renteria VG, Ferrans VJ, Roberts WC. The heart in the Hurler syndrome: gross, histologic and ultrastructural observations in five necropsy cases. Am J Cardiol 1976;38:487-501.
21. Kakkis ED, McEntee MF, Schmidtchen A, et al. Long-term and highdose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 1996;58:156-167. (Pubitemid 26262358)
22. Shull RM, Kakkis ED, McEntee MF, et al. Enzyme replacement in a canine model of Hurler syndrome. Proc Natl Acad Sci USA 1994;91:12937-12941.
23. Passage MB, Krieger AW, Peinovich MC, et al. Continuous infusion of enzyme replacement therapy is inferior to weekly infusions in MPS I dogs. J Inherit Metab Dis 2009; URL: www.springerlink.com/content/0250912230732ng1/.
24. Dickson P, Peinovich M, McEntee M, et al. Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I. J Clin Invest 2008;118:2868-2876.
25. Dickson P, McEntee M, Vogler C, et al. Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 2007;91:61-68. (Pubitemid 46550919)
26. Dickson PI, Hanson S, McEntee MF, et al. Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I. Mol Genet Metab 2010;10:115-122.
27. Dierenfeld AD, McEntee MF, Vogler C, et al. Enzyme therapy from birth normalizes systemic disease and treats the brain in canine mucopolysaccharidosis I. Sci Transl Med 2010;2:60ra89.
28. Hinek A, Wilson SE. Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 2000;156:925-938. (Pubitemid 30626951)
29. Musto L. Modified Movats pentachrome stain. J Histotechnol 1986;9:173-174.
30. McEntee MF, Chiu CH, Whelan J. Relationship of b-catenin and Bcl-2 expression to sulindac induced regression of intestinal tumors in Min mice. Carcinogenesis 1999;20:635-640. (Pubitemid 29151300)
31. Jordan MC, Zheng Y, Ryazantsev S, et al. Cardiac manifestations in the mouse model of mucopolysaccharidosis I. Mol Genet Metab 2005;86:233-243. (Pubitemid 41412180)
32. Cunningham KS, Gotlieb AI. The role of shear stress in the pathogenesis of atherosclerosis. Lab Invest 2005;85:9-23. (Pubitemid 40128037)
33. VanderLaan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis: site-selective responses to atherosclerotic modulators. Arterioscler Thromb Vasc Biol 2004;24:12-22. (Pubitemid 38082406)
34. Hastings NE, Simmers MB, McDonald OG, et al. Atherosclerosis-prone hemodynamics differentially regulates endothelial and smooth muscle cell phenotypes and promotes pro-inflammatory priming. Am J Physiol Cell Physiol 2007;293:C1824-C1833. (Pubitemid 350255075)
35. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: bringing new insights into mechanisms of inflammation and fibrosis. Int J Biochem Cell Biol 2010;42:535-542.
36. Davies PF. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat Clin Pract Cardiovasc Med 2009;6:16-26.
37. Blobe GC, Schiemann WP, Lodish HF. Role of transforming growth factor b in human disease. N Engl J Med 2000;342:1350-1358. (Pubitemid 30408720)
38. Rasmussen LM, Wolf YG, Ruoslahti E. Vascular smooth muscle cells from injured rat aortas display elevated matrix production associated with transforming growth factor-beta activity. Am J Pathol 1995; 147:1041-1048.
39. Wells RG. Fibrogenesis V.TGF-b signaling pathways. Am J Physiol Gastrointest Liver Physiol 2000;279:G845-G850.
40. Norris DA, Clark RA, Swigart LM, et al. Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J Immunol 1982;129:1612-1618. (Pubitemid 12031101)
41. Hocevar BA, Brown TL, Howe PH. TGF-beta induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4- independent pathway. EMBO J 1999;18:1345-1356. (Pubitemid 29110318)
42. Shanmugam N, Roman-Rego A, Ong P, et al. Atherosclerotic plaque regression: fact or fiction? Cardiovasc Drugs Ther 2010;24:311-317.